SCHEMBL11943930

SCHEMBL11943930

CC(Oc1c(N2CCN(S(=O)(=O)C(C)C)CC2)cnn(-c2ccccc2)c1=O)c1c(F)cccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.48
▸ DCTPP1 Q9H773 3/20 0.48
▸ MAPT P10636 1/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.42
▸ POLB P06746 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ NCOA1 Q15788 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ NCOA3 Q9Y6Q9 1/20 0.41
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SCN9A Q15858 1/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ SLC2A3 P11169 1/20 0.39
▸ MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945034 0.90 ALDH1A1 (0.55) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11943947 0.88 MAPT (0.52) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11943981 0.84 ALDH1A1 (0.48) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11945059 0.84 ALDH1A1 (0.55) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11945252 0.81 MAPT (0.52) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11944265 0.81 POLB (0.49) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11944101 0.80 ALDH1A1 (0.51) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11944535 0.80 MAPT (0.53) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL11945050 0.80 MAPT (0.51) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB
SCHEMBL17058296 0.80 SMN1; SMN2 (0.39) ALDH1A1DCTPP1MAPTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885MAPT 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback